AIM
ALLO icon

Aigen Investment Management’s Allogene Therapeutics ALLO Stock Holding History

Aigen Investment Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-15,416
Closed -$21.1K – 512
2025
Q4 		$21.1K Buy
+15,416
New +$20.3K ﹤0.01% 549
2021
Q2 		– Sell
-11,616
Closed -$410K – 446
2021
Q1 		$410K Sell
11,616
-16,438
-59% -$554K 0.05% 337
2020
Q4 		$708K Buy
+28,054
New +$914K 0.09% 291
2020
Q2 		– Sell
-22,499
Closed -$437K – 796
2020
Q1 		$437K Buy
22,499
+8,128
+57% +$194K 0.06% 460
2019
Q4 		$373K Buy
+14,371
New +$396K 0.06% 392

Other funds holding ALLO

P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aigen Investment Management's ALLO Position: Q1 2026 in Review

Aigen Investment Management sold out of Allogene Therapeutics (ALLO) in Q1 2026, closing a stake of 15,416 shares — an estimated $21.1K sold.

Aigen Investment Management first reported a position in ALLO in Q4 2019 and held it in 5 quarters. The position peaked at $708K in Q4 2020. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Aigen Investment Management reported no remaining Allogene Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aigen Investment Management sold 15,416 Allogene Therapeutics shares in Q1 2026, an estimated $21.1K.
  • Aigen Investment Management first reported a position in Allogene Therapeutics in Q4 2019 and held it in 5 quarters.
  • Aigen Investment Management's Allogene Therapeutics position peaked at $708K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Aigen Investment Management's 13F filing for Q1 2026, filed 15 May 2026.